Results 251 to 260 of about 17,373,161 (316)

CDK4/6 Inhibition Induces CD8+ T Cell Antitumor Immunity via MIF‐Induced Functional Orchestration of Tumor‐Associated Macrophages

Advanced Science, EarlyView.
CDK4/6 inhibition promotes CD8+ T cell expansion through tumor‐macrophage crosstalk by activating HIF‐1α and enhancing MIF‐CD44/CD74 signaling. This reprograms TAMs to boost MHC‐I antigen presentation, and CDK4/6 inhibitor‐trained M1 TAM supernatant therapy synergizes with low‐dose PD‐1 blockade to restore antitumor immunity.
Lin He, Yuzhong Peng, Lat‐lun Leong, Jingbo Zhou, Dongyang Tang, Weilu Wang, Xiaoran Wu, Josh haipeng Lei, Yongqin Ye, Yangyang Feng, Yunfeng Qiao, Xiangpeng Chu, Di Mu, Qi Zhao, Tzuming Liu, Yan Chen, Paul Kwonghang Tam, Chu‐Xia Deng   +17 more
wiley   +1 more source

BCMA-CD19 armored compound CAR T cells in systemic lupus erythematosus: extended follow-up of a phase 1 clinical trial. [PDF]

J Hematol Oncol
Hong M, Wang M, Zeng R, Ding L, He S, Lan T, DeStefano VM, Wada M, Pinz K, Chow JE, Choi BH, Hagag N, Wang M, Ma Y, Luo J, Liang Y, Ding S, Lu Z, Zhang W, Ma Y, Wang W.   +20 more
europepmc   +1 more source

Development of Endogenous Protein Probes for Characterizing Surface Proteins and Cellular Interactors of Extracellular Vesicles

Advanced Science, EarlyView.
The proximity labeling enzyme APEX2 is displayed on extracellular vesicle (EV) surfaces via genetic fusion with EV‐sorting scaffolds, enabling in situ biotinylation of native surface proteins, adsorbed corona components, and interacting cellular proteins.
Wenyi Zheng, Metoboroghene Mowoe, Wenqing Hou, Daniel W. Hagey, Koshi Imami, Samir EL Andaloussi   +5 more
wiley   +1 more source

Advancing breast cancer treatment through dual targeting CAR T cell therapy. [PDF]

Discov Oncol
Sheikh M, Madia D, Telrandhe UB, Bagga H, Deshmukh A.   +4 more
europepmc   +1 more source

Aberrant SUMOylation Restricts the Targetable Cancer Immunopeptidome

Advanced Science, EarlyView.
Pharmacological SUMOylation inhibition (SUMOi) counteracts tumor immune evasion by unmasking an immunogenic HLA‐I peptide and neoepitope repertoire. By restoring HLA‐I ligand availability through increased antigen processing and presentation, enhanced proteasomal cleavage, and modulated TAP1 peptide affinity, SUMOi boosts tumor immunogenicity ...
Uta M. Demel, Anna Meurer, Badeel Kh. Q. Zaghla, Bilge Atay, Daniel Steiert, Luca V. Hummel, Konstandina Isaakidis, Chuanbing Zang, Michael Korenkov, Marlon Schielin, Schayan Yousefian, Shima Mecklenbräuker, Marieluise Kirchner, Simon Haas, Antonia Busse, Philipp Mertins, Stefan Müller, Matthias Wirth, Martin G. Klatt, Ulrich Keller   +19 more
wiley   +1 more source

CAR-T therapy in non-small cell lung cancer: Clinical prospects, potential, and strategies for cardiotoxicity management. [PDF]

Transl Oncol
Liu Y, Gao Y, Huo C, Zeng T, Meng W, Zhang H, He Q.   +6 more
europepmc   +1 more source

rWTC‐MBTA Vaccine, Alone and Enhanced with Anti‐PD1, Elicits Immune Responses against CNS and Peripheral B‐Cell Lymphoma

Advanced Science, EarlyView.
An autologous whole‐tumor‐cell vaccine (rWTC‐MBTA) is evaluated in murine CNS lymphoma. Subcutaneous vaccination activates dendritic cells, broadens T‐cell priming, and drives lymphocyte trafficking to brain tumors, producing durable tumor control. Longitudinal bioluminescence and adoptive‐transfer assays verify CNS engagement. Combination with anti‐PD‐
Yaping Zhang, Juan Ye, Mitchell Sun, Samik Chakraborty, Alex Valenzuela, Shuran Chen, Qingfeng Xue, Wenyu Shi, Karel Pacak, Herui Wang, Zhengping Zhuang   +10 more
wiley   +1 more source

Engineering CAR T NK and NKT cell therapies to target cancer stem cells and overcome stem like resistance. [PDF]

Discov Oncol
Allela OQB, Shareef A, Jyothi SR, Nayak PP, Janney JB, Singh G, Chauhan AS, Oripov F, Sameer HN, Yaseen A, Salih RM, Adil M.   +11 more
europepmc   +1 more source